BioForm Medical closes initial public offer of stock

Including the over-allotment, the company sold 11.5 million shares in the offering, resulting in net proceeds of approximately $83.4 million after deducting the underwriting discounts and commission and the estimated offering expenses.

The underwriters of the offering have exercised their over-allotment option in full and purchased 1.5 million additional shares of common stock at the public offering price of $8 per share.

JP Morgan Securities and Piper Jaffray & Co. served as joint book-running managers for the offering, with CIBC World Markets and Jefferies & Company, acting as co-managers.